Last updated on April 18, 2014 at 6:54 EDT

Latest Orteronel Stories

2013-03-18 08:26:43

Downstream Cost Savings, Will Encourage EU5 Payers to Think Beyond the Price Tag, Although Drug Cost Must Be Well Balanced Against Potential Uptake, According to a New Report from Decision Resources BURLINGTON, Mass., March 18, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite its recent market entry, Johnson & Johnson/Janssen Biotech/Janssen Cilag's Zytiga has heavily...